Tokyo Tape
Sign in
← M3

Quarterly report · Q3

2413.TEDINET S100Q51B
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥154.2bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥56.5bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥84.6bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥22.7bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥85.2bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.9bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥56.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.4bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥58.5bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥15.8bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥380.7bnat 2022-12-31Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥324.8bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥83.4bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥252.7bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥246.6bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.3bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥31.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥10.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥15.6bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥82.752021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.662021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥82.682021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.642021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue intersegment2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2021-12-31−¥803m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥11.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥2.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥10.6bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥2.7bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥465m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥102m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥582m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥16.2bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥6.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥15.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥710m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥227m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-12-31¥64.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-10-01 → 2021-12-31¥26.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-12-31¥62.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-10-01 → 2021-12-31¥25.6bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥2.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥674m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-12-31¥30.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-10-01 → 2021-12-31¥14.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-12-31¥37.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-12-31¥37.8bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥5m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-12-31¥41.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-10-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥25.7bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥8.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥25.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥438m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥200m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥2.0bn
—segment totalrevenue2021-04-01 → 2021-12-31¥155.4bn
—segment totalrevenue2021-10-01 → 2021-12-31¥56.8bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥151.8bn
—segment totalrevenue external2021-10-01 → 2021-12-31¥55.6bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥3.6bn
—segment totalrevenue intersegment2021-10-01 → 2021-12-31¥1.2bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥84.7bn
—segment totalsegment profit2021-10-01 → 2021-12-31¥21.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 789
ItemContextValueUnit
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember2915000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember8751000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember17056000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_ReportableSegmentsMember61633000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember905000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentQuarterDuration62538000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember739000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember174000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember178000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember17000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_ReportableSegmentsMember1108000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember24000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_ReconcilingItemsMember-1132000000JPY
Intersegment revenue IFRSCurrentQuarterDuration－JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember27226000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember6598000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember3093000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember8751000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember17073000000JPY
Revenue IFRSCurrentQuarterDuration_ReportableSegmentsMember62741000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember929000000JPY
Revenue IFRSCurrentQuarterDuration_ReconcilingItemsMember-1132000000JPY
Revenue IFRSCurrentQuarterDuration62538000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember13326000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember1799000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember734000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember917000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember5806000000JPY
Operating profit loss IFRSCurrentQuarterDuration_ReportableSegmentsMember22582000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember277000000JPY
Operating profit loss IFRSCurrentQuarterDuration_ReconcilingItemsMember-418000000JPY
Operating profit loss IFRSCurrentQuarterDuration22441000000JPY
Finance income and expenses net IFRSCurrentQuarterDuration-258000000JPY
Profit loss before tax IFRSCurrentQuarterDuration22183000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember703000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember139000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember25000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember248000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember668000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_ReportableSegmentsMember1782000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember67000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_ReconcilingItemsMember－JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration1849000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-02-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第23期第３四半期（自　2022年10月１日　至　2022年12月31日）

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass